Annals of Oncology 15:1007-1012, 2004
© 2004 European Society for Medical Oncology
Review |
Pharmacological background of EGFR targeting
Epidermal growth factor receptor (EGFR) signaling pathways play a key role in the regulation of cell proliferation, survival and differentiation. As a consequence, EGFR is one of the best studied ligand–receptor system and specific EGFR inhibition approaches are currently among the most promising and the most advanced in the clinical setting. Monoclonal antibodies (mAbs) and specific tyrosine kinase inhibitors (TKIs) have been developed, among which C225 (Cetuximab) and ZD1839 (Iressa), respectively, are the most advanced. The aim of the present review was not to cover the field of EGFR inhibitors, but to compare at experimental and clinical levels the different key points governing the actions of mAbs and TKIs. In addition, combinations of conventional chemotherapies with EGFR targeting drugs, as well as resistance mechanisms of EGFR targeting, have been reviewed.
1 Otorhinolaryngology Department, Nice General Hospital; 2 Oncopharmacology Unit, Centre Antoine-Lacassagne, Nice, France
*Correspondence to: Dr G. Milano, Oncopharmacology Unit, Centre Antoine-Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France. Tel: +33-4-92-03-15-53; Fax: +33-4-93-81-71-31; Email: gerard.milano{at}nice.fnclcc.fr
Key words: Cetuximab, epidermal growth factor receptor, Iressa, targeted treatment, tyrosine kinase inhibitor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Tolmachev, M. Friedman, M. Sandstrom, T. L.J. Eriksson, D. Rosik, M. Hodik, S. Stahl, F. Y. Frejd, and A. Orlova Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry J. Nucl. Med., February 1, 2009; 50(2): 274 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers Oncologist, December 1, 2007; 12(12): 1443 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wu, W. Yang, R. F. Barth, S. Kawabata, M. Swindall, A. K. Bandyopadhyaya, W. Tjarks, B. Khorsandi, T. E. Blue, A. K. Ferketich, et al. Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor-Positive Glioma Using Boronated Cetuximab Clin. Cancer Res., February 15, 2007; 13(4): 1260 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. El-Deiry, C. C. Sigman, and G. J. Kelloff Imaging and Oncologic Drug Development J. Clin. Oncol., July 10, 2006; 24(20): 3261 - 3273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Y. S. Tam, L. P. Chung, W. S. Suen, E. Wang, M. C.M. Wong, K. K. Ho, W. K. Lam, S. W. Chiu, L. Girard, J. D. Minna, et al. Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non-Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features Clin. Cancer Res., March 1, 2006; 12(5): 1647 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Frieze and J. S McCune Current Status of Cetuximab for the Treatment of Patients with Solid Tumors Ann. Pharmacother., February 1, 2006; 40(2): 241 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Velikyan, A. L. Sundberg, O. Lindhe, A. U. Hoglund, O. Eriksson, E. Werner, J. Carlsson, M. Bergstrom, B. Langstrom, and V. Tolmachev Preparation and Evaluation of 68Ga-DOTA-hEGF for Visualization of EGFR Expression in Malignant Tumors J. Nucl. Med., November 1, 2005; 46(11): 1881 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Segaert and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann. Onc., September 1, 2005; 16(9): 1425 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Etienne-Grimaldi, S. Pereira, N. Magne, J.-L. Formento, M. Francoual, X. Fontana, F. Demard, O. Dassonville, G. Poissonnet, J. Santini, et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients Ann. Onc., June 1, 2005; 16(6): 934 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tonini, B. Vincenzi, D. Santini, D. Olzi, A. Lambiase, and S. Bonini Ocular Toxicity Related to Cetuximab Monotherapy in an Advanced Colorectal Cancer Patient J Natl Cancer Inst, April 20, 2005; 97(8): 606 - 607. [Full Text] [PDF]
|
|
|
|
 |
|
 D. McKillop, E. A. Partridge, J. V. Kemp, M. P. Spence, J. Kendrew, S. Barnett, P. G. Wood, P. B. Giles, A. B. Patterson, F. Bichat, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor Mol. Cancer Ther., April 1, 2005; 4(4): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Scartozzi, I. Bearzi, R. Berardi, A. Mandolesi, G. Fabris, and S. Cascinu Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies J. Clin. Oncol., December 1, 2004; 22(23): 4772 - 4778. [Abstract] [Full Text] [PDF]
|
|